ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,569 | -29.8% | 1,972,484 | -1.3% | 0.03% | -26.3% |
| Q2 2023 | $56,402 | +63.1% | 1,999,354 | -0.5% | 0.04% | +52.0% |
| Q1 2023 | $34,580 | -22.3% | 2,010,409 | -9.0% | 0.02% | -26.5% |
| Q4 2022 | $44,519 | -99.9% | 2,210,442 | +0.1% | 0.03% | -10.5% |
| Q3 2022 | $47,840,000 | – | 2,208,669 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
| Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
| Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
| Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
| Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
| Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
| Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
| Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
| SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |